Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission

Martin S. Tallman, Waleska S. Pérez, Hillard M. Lazarus, Robert Peter Gale, Richard Maziarz, Jacob M. Rowe, David I. Marks, Jean Yves Cahn, Asad Bashey, Michael R. Bishop, Neal Christiansen, Stanley R. Frankel, Juan J. García, Osman Ilhan, Mary J. Laughlin, Jane Liesveld, Charles Linker, Mark R. Litzow, Selina Luger, Philip L. McCarthyGustavo A. Milone, Santiago Pavlovsky, Gordon L. Phillips, James A. Russell, Ruben A. Saez, Gary Schiller, Jorge Sierra, Roy S. Weiner, Axel R. Zander, Mei Jie Zhang, Armand Keating, Daniel J. Weisdorf, Mary M. Horowitz

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Controversy exists over whether pretransplantation consolidation chemotherapy affects the outcome of subsequent autotransplantation for acute myelogenous leukemia (AML). The current study was undertaken to determine the association between previous consolidation and outcome of autotransplantation for AML in first remission. Posttransplantation outcomes of 146 patients receiving no consolidation were compared with those of 244 patients receiving standard-dose (2) and 249 patients receiving high-dose (1-3 gm/m2) cytarabine, using proportional hazards regression to adjust for differences in prognostic variables. One-year transplantation-related mortality was similar among the cohorts. Five-year relapse rates were 49% (95% confidence interval CI = 39%-58%) with no consolidation, 35% (95% CI = 29%-42%) with standard-dose cytarabine, and 40% (95% CI = 33%-48%) with high-dose cytarabine (P = .07). Five-year leukemia-free survival rates were 39% (95% CI = 30%-47%) with no consolidation, 53% (95% CI = 46%-60%) with standard-dose cytarabine, and 48% (95% CI = 40%-56%) with high-dose cytarabine (P = .03). Similarly, 5-year overall survival was better in those patients receiving consolidation: 42% (95% CI = 34%-51%) with no consolidation, 59% (95% CI = 52%-65%) with standard-dose cytarabine, and 54% (95% CI = 46%-61%) with high-dose cytarabine (P = .01). Although most patients received 1 or 2 cycles of consolidation, the number of courses had no detectable effect on transplantation outcome. In multivariate analysis, risks of relapse and treatment failure were lower in the patients receiving consolidation, especially among those patients receiving blood cell grafts. Outcomes with standard-dose and high-dose cytarabine were similar. Based on our findings, we recommend that patients with AML in first remission receive consolidation before undergoing autotransplantation.

Original languageEnglish (US)
Pages (from-to)204-216
Number of pages13
JournalBiology of Blood and Marrow Transplantation
Volume12
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Consolidation Chemotherapy
Cytarabine
Acute Myeloid Leukemia
Leukemia
Bone Marrow
Transplants
Recurrence
Autologous Transplantation
Transplantation
Treatment Failure
Blood Cells
Multivariate Analysis
Survival Rate
Confidence Intervals

Keywords

  • Acute myelogenous leukemia
  • Autologous
  • Autotransplantation
  • Consolidation
  • Transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. / Tallman, Martin S.; Pérez, Waleska S.; Lazarus, Hillard M.; Gale, Robert Peter; Maziarz, Richard; Rowe, Jacob M.; Marks, David I.; Cahn, Jean Yves; Bashey, Asad; Bishop, Michael R.; Christiansen, Neal; Frankel, Stanley R.; García, Juan J.; Ilhan, Osman; Laughlin, Mary J.; Liesveld, Jane; Linker, Charles; Litzow, Mark R.; Luger, Selina; McCarthy, Philip L.; Milone, Gustavo A.; Pavlovsky, Santiago; Phillips, Gordon L.; Russell, James A.; Saez, Ruben A.; Schiller, Gary; Sierra, Jorge; Weiner, Roy S.; Zander, Axel R.; Zhang, Mei Jie; Keating, Armand; Weisdorf, Daniel J.; Horowitz, Mary M.

In: Biology of Blood and Marrow Transplantation, Vol. 12, No. 2, 02.2006, p. 204-216.

Research output: Contribution to journalArticle

Tallman, MS, Pérez, WS, Lazarus, HM, Gale, RP, Maziarz, R, Rowe, JM, Marks, DI, Cahn, JY, Bashey, A, Bishop, MR, Christiansen, N, Frankel, SR, García, JJ, Ilhan, O, Laughlin, MJ, Liesveld, J, Linker, C, Litzow, MR, Luger, S, McCarthy, PL, Milone, GA, Pavlovsky, S, Phillips, GL, Russell, JA, Saez, RA, Schiller, G, Sierra, J, Weiner, RS, Zander, AR, Zhang, MJ, Keating, A, Weisdorf, DJ & Horowitz, MM 2006, 'Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission', Biology of Blood and Marrow Transplantation, vol. 12, no. 2, pp. 204-216. https://doi.org/10.1016/j.bbmt.2005.10.013
Tallman, Martin S. ; Pérez, Waleska S. ; Lazarus, Hillard M. ; Gale, Robert Peter ; Maziarz, Richard ; Rowe, Jacob M. ; Marks, David I. ; Cahn, Jean Yves ; Bashey, Asad ; Bishop, Michael R. ; Christiansen, Neal ; Frankel, Stanley R. ; García, Juan J. ; Ilhan, Osman ; Laughlin, Mary J. ; Liesveld, Jane ; Linker, Charles ; Litzow, Mark R. ; Luger, Selina ; McCarthy, Philip L. ; Milone, Gustavo A. ; Pavlovsky, Santiago ; Phillips, Gordon L. ; Russell, James A. ; Saez, Ruben A. ; Schiller, Gary ; Sierra, Jorge ; Weiner, Roy S. ; Zander, Axel R. ; Zhang, Mei Jie ; Keating, Armand ; Weisdorf, Daniel J. ; Horowitz, Mary M. / Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. In: Biology of Blood and Marrow Transplantation. 2006 ; Vol. 12, No. 2. pp. 204-216.
@article{d76e0c2c4fe14849803f79656ee77f5a,
title = "Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission",
abstract = "Controversy exists over whether pretransplantation consolidation chemotherapy affects the outcome of subsequent autotransplantation for acute myelogenous leukemia (AML). The current study was undertaken to determine the association between previous consolidation and outcome of autotransplantation for AML in first remission. Posttransplantation outcomes of 146 patients receiving no consolidation were compared with those of 244 patients receiving standard-dose (2) and 249 patients receiving high-dose (1-3 gm/m2) cytarabine, using proportional hazards regression to adjust for differences in prognostic variables. One-year transplantation-related mortality was similar among the cohorts. Five-year relapse rates were 49{\%} (95{\%} confidence interval CI = 39{\%}-58{\%}) with no consolidation, 35{\%} (95{\%} CI = 29{\%}-42{\%}) with standard-dose cytarabine, and 40{\%} (95{\%} CI = 33{\%}-48{\%}) with high-dose cytarabine (P = .07). Five-year leukemia-free survival rates were 39{\%} (95{\%} CI = 30{\%}-47{\%}) with no consolidation, 53{\%} (95{\%} CI = 46{\%}-60{\%}) with standard-dose cytarabine, and 48{\%} (95{\%} CI = 40{\%}-56{\%}) with high-dose cytarabine (P = .03). Similarly, 5-year overall survival was better in those patients receiving consolidation: 42{\%} (95{\%} CI = 34{\%}-51{\%}) with no consolidation, 59{\%} (95{\%} CI = 52{\%}-65{\%}) with standard-dose cytarabine, and 54{\%} (95{\%} CI = 46{\%}-61{\%}) with high-dose cytarabine (P = .01). Although most patients received 1 or 2 cycles of consolidation, the number of courses had no detectable effect on transplantation outcome. In multivariate analysis, risks of relapse and treatment failure were lower in the patients receiving consolidation, especially among those patients receiving blood cell grafts. Outcomes with standard-dose and high-dose cytarabine were similar. Based on our findings, we recommend that patients with AML in first remission receive consolidation before undergoing autotransplantation.",
keywords = "Acute myelogenous leukemia, Autologous, Autotransplantation, Consolidation, Transplantation",
author = "Tallman, {Martin S.} and P{\'e}rez, {Waleska S.} and Lazarus, {Hillard M.} and Gale, {Robert Peter} and Richard Maziarz and Rowe, {Jacob M.} and Marks, {David I.} and Cahn, {Jean Yves} and Asad Bashey and Bishop, {Michael R.} and Neal Christiansen and Frankel, {Stanley R.} and Garc{\'i}a, {Juan J.} and Osman Ilhan and Laughlin, {Mary J.} and Jane Liesveld and Charles Linker and Litzow, {Mark R.} and Selina Luger and McCarthy, {Philip L.} and Milone, {Gustavo A.} and Santiago Pavlovsky and Phillips, {Gordon L.} and Russell, {James A.} and Saez, {Ruben A.} and Gary Schiller and Jorge Sierra and Weiner, {Roy S.} and Zander, {Axel R.} and Zhang, {Mei Jie} and Armand Keating and Weisdorf, {Daniel J.} and Horowitz, {Mary M.}",
year = "2006",
month = "2",
doi = "10.1016/j.bbmt.2005.10.013",
language = "English (US)",
volume = "12",
pages = "204--216",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission

AU - Tallman, Martin S.

AU - Pérez, Waleska S.

AU - Lazarus, Hillard M.

AU - Gale, Robert Peter

AU - Maziarz, Richard

AU - Rowe, Jacob M.

AU - Marks, David I.

AU - Cahn, Jean Yves

AU - Bashey, Asad

AU - Bishop, Michael R.

AU - Christiansen, Neal

AU - Frankel, Stanley R.

AU - García, Juan J.

AU - Ilhan, Osman

AU - Laughlin, Mary J.

AU - Liesveld, Jane

AU - Linker, Charles

AU - Litzow, Mark R.

AU - Luger, Selina

AU - McCarthy, Philip L.

AU - Milone, Gustavo A.

AU - Pavlovsky, Santiago

AU - Phillips, Gordon L.

AU - Russell, James A.

AU - Saez, Ruben A.

AU - Schiller, Gary

AU - Sierra, Jorge

AU - Weiner, Roy S.

AU - Zander, Axel R.

AU - Zhang, Mei Jie

AU - Keating, Armand

AU - Weisdorf, Daniel J.

AU - Horowitz, Mary M.

PY - 2006/2

Y1 - 2006/2

N2 - Controversy exists over whether pretransplantation consolidation chemotherapy affects the outcome of subsequent autotransplantation for acute myelogenous leukemia (AML). The current study was undertaken to determine the association between previous consolidation and outcome of autotransplantation for AML in first remission. Posttransplantation outcomes of 146 patients receiving no consolidation were compared with those of 244 patients receiving standard-dose (2) and 249 patients receiving high-dose (1-3 gm/m2) cytarabine, using proportional hazards regression to adjust for differences in prognostic variables. One-year transplantation-related mortality was similar among the cohorts. Five-year relapse rates were 49% (95% confidence interval CI = 39%-58%) with no consolidation, 35% (95% CI = 29%-42%) with standard-dose cytarabine, and 40% (95% CI = 33%-48%) with high-dose cytarabine (P = .07). Five-year leukemia-free survival rates were 39% (95% CI = 30%-47%) with no consolidation, 53% (95% CI = 46%-60%) with standard-dose cytarabine, and 48% (95% CI = 40%-56%) with high-dose cytarabine (P = .03). Similarly, 5-year overall survival was better in those patients receiving consolidation: 42% (95% CI = 34%-51%) with no consolidation, 59% (95% CI = 52%-65%) with standard-dose cytarabine, and 54% (95% CI = 46%-61%) with high-dose cytarabine (P = .01). Although most patients received 1 or 2 cycles of consolidation, the number of courses had no detectable effect on transplantation outcome. In multivariate analysis, risks of relapse and treatment failure were lower in the patients receiving consolidation, especially among those patients receiving blood cell grafts. Outcomes with standard-dose and high-dose cytarabine were similar. Based on our findings, we recommend that patients with AML in first remission receive consolidation before undergoing autotransplantation.

AB - Controversy exists over whether pretransplantation consolidation chemotherapy affects the outcome of subsequent autotransplantation for acute myelogenous leukemia (AML). The current study was undertaken to determine the association between previous consolidation and outcome of autotransplantation for AML in first remission. Posttransplantation outcomes of 146 patients receiving no consolidation were compared with those of 244 patients receiving standard-dose (2) and 249 patients receiving high-dose (1-3 gm/m2) cytarabine, using proportional hazards regression to adjust for differences in prognostic variables. One-year transplantation-related mortality was similar among the cohorts. Five-year relapse rates were 49% (95% confidence interval CI = 39%-58%) with no consolidation, 35% (95% CI = 29%-42%) with standard-dose cytarabine, and 40% (95% CI = 33%-48%) with high-dose cytarabine (P = .07). Five-year leukemia-free survival rates were 39% (95% CI = 30%-47%) with no consolidation, 53% (95% CI = 46%-60%) with standard-dose cytarabine, and 48% (95% CI = 40%-56%) with high-dose cytarabine (P = .03). Similarly, 5-year overall survival was better in those patients receiving consolidation: 42% (95% CI = 34%-51%) with no consolidation, 59% (95% CI = 52%-65%) with standard-dose cytarabine, and 54% (95% CI = 46%-61%) with high-dose cytarabine (P = .01). Although most patients received 1 or 2 cycles of consolidation, the number of courses had no detectable effect on transplantation outcome. In multivariate analysis, risks of relapse and treatment failure were lower in the patients receiving consolidation, especially among those patients receiving blood cell grafts. Outcomes with standard-dose and high-dose cytarabine were similar. Based on our findings, we recommend that patients with AML in first remission receive consolidation before undergoing autotransplantation.

KW - Acute myelogenous leukemia

KW - Autologous

KW - Autotransplantation

KW - Consolidation

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=31344460389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31344460389&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2005.10.013

DO - 10.1016/j.bbmt.2005.10.013

M3 - Article

C2 - 16443518

AN - SCOPUS:31344460389

VL - 12

SP - 204

EP - 216

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -